Lynch on the BEL20
This ranking weighs PEG ×4, Revenue growth ×3, ROE ×2, Analyst upside ×1, Buy % ×1, and nothing else, across the 20 companies we track on the BEL20. 5 of them clear Lynch’s hard limits right now, and 3 cannot be judged because a required figure is missing.
Ranked highest by Lynch on this market right now, which is not the same list as the one that clears the limits above:
- argenx (ARGX.BR) · Healthcare · PEG 1.22 · Revenue growth 59.3% · ROE 24% · Analyst upside 17.8% · Buy % 87%
- UCB (UCB.BR) · Healthcare · PEG 1.10 · Revenue growth 22.5% · ROE 21% · Analyst upside 41.3% · Buy % 75%
- Aedifica (AED.BR) · Real Estate · Revenue growth 104.3% · ROE 12% · Analyst upside 26.4% · Buy % 80%
- Umicore (UMI.BR) · Industrials · PEG 2.62 · Revenue growth 60.1% · ROE 23% · Analyst upside 15.9% · Buy % 53%
- AB InBev (ABI.BR) · Consumer Defensive · PEG 1.64 · Revenue growth 11.0% · ROE 11% · Analyst upside 21.1% · Buy % 80%
From data as of 2026-09-11 03:00:56 UTC. Rebuilt every hour; the table above is live.